Option Care Health — Third Quarter 2026 Earnings Summary

Financial Performance:

• Net revenue for the quarter ended September 30, 2026, was $1,493.5 million, an increase of 4.1% year-over-year compared to $1,435.0 million in the prior year period.
• GAAP net income was $57.4 million, up 10.8% from $51.8 million in the same period last year.
• GAAP diluted earnings per share (EPS) were $0.38, representing an 18.8% increase from $0.32 in the prior year period.
• Adjusted EBITDA was $124.6 million, up 4.3% year-over-year from $119.5 million.
• Adjusted diluted EPS was $0.49, an 8.9% increase from $0.45 in the prior year period.
• Cash provided by operating activities for the quarter was $114.7 million.
• For the nine months ended September 30, 2026, net revenue was $4,286.6 million compared to $4,184.1 million in the prior year period.
• For the nine months ended September 30, 2026, GAAP net income was $156.7 million compared to $149.1 million in the prior year period.
• For the nine months ended September 30, 2026, Adjusted EBITDA was $346.9 million compared to $345.3 million in the prior year period.
• Long-term debt, net of discount and current portion, stood at $1,151.1 million as of September 30, 2026, compared to $1,154.1 million as of December 31, 2025.
• Cash and cash equivalents were $299.1 million as of September 30, 2026, compared to $232.6 million as of December 31, 2025.

Guidance and Future Outlook:

• The Company has withdrawn its previously disclosed financial guidance due to the pending acquisition.
• The Company will not host an earnings conference call in connection with these results.

Business Segments and Product Lines:

• No specific segment or product line performance data is provided in the press release.

Market and Competitive Landscape:

• No specific market share, competitive landscape, or market trend data is provided in the press release.

Risks and Challenges:

• Risks include the potential termination of the merger agreement, failure to obtain regulatory or stockholder approval, and delays in closing the transaction.
• Risks include potential litigation related to the transaction, costs associated with the transaction, and restrictions on business operations during the pendency of the transaction.
• Risks include the potential adverse effect of the transaction on the Company's stock price, credit ratings, ability to retain key personnel, and relationships with customers, suppliers, and managed care organizations.
• Risks include changes in laws, regulations, trade policies, and the pharmaceutical industry that could impact the business model.

Management Commentary and Tone:

• No specific management commentary or quoted remarks are included in the press release.

Analyst Questions and Answers:

• No analyst questions and answers are included in the press release.

Other Key Points:

• The Company has entered into a definitive merger agreement to be acquired by Clayton, Dubilier & Rice, LLC and McKesson Corporation.
• The Company is the nation's largest independent provider of home and alternate site infusion services, employing over 8,000 team members, including more than 5,000 clinicians.
• For the nine months ended September 30, 2026, the Company used $192.1 million in cash for financing activities, primarily driven by the purchase of company stock and related excise taxes of $170.5 million.
• For the nine months ended September 30, 2026, the Company used $27.7 million in cash for investing activities, primarily for the acquisition of property and equipment.
• Restructuring, acquisition, integration, and other expenses were $5.6 million for the quarter and $13.8 million for the nine months ended September 30, 2026.
• Stock-based incentive compensation expense was $9.3 million for the quarter and $27.9 million for the nine months ended September 30, 2026.